Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06832189 · ClinicalTrials.gov registry record · Phase 1
EVR and EPO for Liver Transplant Tolerance
A Phase 1 study of Liver Transplant, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Recruiting
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 3
- Study locations
NCT06832189: Recruiting Phase 1 study of Liver Transplant, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT06832189 is a Phase 1 study of Liver Transplant that is actively recruiting participants, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 20 participants, below the 5,457-participant average among 19 other Liver Transplant trials with a reported enrollment target (100% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06832189, a Phase 1 study of Liver Transplant, is actively recruiting participants, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is an open label, single-arm, multicenter phase 1b study of stable adult liver transplant recipients on a tacrolimus (TAC)-based immunosuppression (IS) regimen who will transition from TAC to Everolimus (EVR), receive five doses of EPO and concurrently initiate phased withdrawal from EVR. The primary objective is to test the safety of administering Everolimus (EVR) and epoetin alfa (EPO) to induce operational tolerance in stable adult liver transplant recipients
Primary Outcome
The primary analysis will be performed using the Intention-to-Treat (ITT) and Per-Protocol (PP) analysis populations, and the proportion will be summarized with a point estimate and a two-sided, 95% confidence interval (CI) calculated using the Clopper-Pearson (exact) method
Conditions Studied
Interventions
- DRUG Everolimus
- DRUG Epoetin alfa
Study Locations (3)
California
- University of California San Francisco School of Medicine - San Francisco
Illinois
- Northwestern University Feinberg School of Medicine - Chicago
Pennsylvania
- University of Pennsylvania Medical Center - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2026-01-21 |
| Est. Completion | 2030-06-01 |
| Phase | Phase 1 |
What NCT06832189 shows while recruiting
NCT06832189 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 5,457-participant average among 19 other Liver Transplant trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Liver Transplant appearing as the primary indexed condition, and to 2 interventions - of which Everolimus is the first listed.
NCT06832189 reports a single indexed study location in California, Illinois, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06832189 about?
NCT06832189 is a clinical study titled "EVR and EPO for Liver Transplant Tolerance". This is an open label, single-arm, multicenter phase 1b study of stable adult liver transplant recipients on a tacrolimus (TAC)-based immunosuppression (IS) regimen who will transition from TAC to Everolimus (EVR), receive five doses of EPO and concurrently initiate phased withdrawal from EVR. The ...
What is the current status of trial NCT06832189?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2026-01-21. Estimated completion is 2030-06-01.
What conditions does trial NCT06832189 study?
This clinical trial studies the following conditions: Liver Transplant.
What interventions are being tested in trial NCT06832189?
The interventions under investigation include: Everolimus (DRUG), Epoetin alfa (DRUG).
Who is sponsoring clinical trial NCT06832189?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06832189 being conducted?
This trial has 3 study locations across California, Illinois, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Liver Transplant
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06832189's enrollment target sits among peer trials
20 18th of 19 higher than 2 of 19 other Liver Transplant trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Liver Transplant trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Liver Transplantation With Tregs at MGH
ACTIVE NOT RECRUITING · Phase 1
-
Expanding Liver Transplant Immunosuppression Minimization Via Everolimus
RECRUITING · Phase 2
-
US National OCS Liver Perfusion (OLP) Registry
RECRUITING
-
Liver Transplant CGM
RECRUITING
-
Auriculo-Nerve Stimulation on Post-Operative Opioid Requirement
RECRUITING · NA
-
Cytomegalovirus (CMV) Vaccine in Orthotopic Liver Transplant Candidates
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI